Table 3.

Clinicopathologic characteristics of seven patients positive for RET rearrangements

Study	Age (years)	Sex	Race	Smoking status*	Histology	EGFRstatus	KRASstatus	Dose/day	Exposure	RECIST response	Tumor shrinkage	Reason for discontinuation	RET partner	% cells with rearrangements detected
Vandetanib
ZODIAC	68	F	Asian	Non-smoker	Adenocarcinoma	Mutation negative	Negative	100 mg	21 days	Progressive disease	–	Progressive disease	KIF5B	50%
ZEPHYR	69	F	White	Non-smoker	Adenocarcinoma	Mutation negative; amplification positive	Negative	300 mg	180 days	Stable disease	23% shrinkage of target lesions	Adverse event	KIF5B	75–100%
ZEPHYR	59	F	Asian	Non-smoker	Adenocarcinoma	Mutation negative; amplification positive	Negative	300 mg	57 days	Progressive disease	33% shrinkage of target lesions (progressive disease in non-target lesions)	Progressive disease	KIF5B	50–75%
Comparator
ZODIAC	59	F	White	Ex-smoker	Adenocarcinoma	Mutation negative	Unknown	–	Six cycles docetaxel	Partial response (day 85); progressive disease (day 210)	32% shrinkage of target lesions at day 85	Completed six cycles	KIF5B	75–100%
ZEAL**	58	M	White	Ex-smoker	Large cell carcinoma	Mutation negative	Negative	–	Five cycles pemetrexed	Progressive disease (day 245)	None	Completed five cycles	Not known	75–100%
ZEPHYR	57	M	White	Ex-smoker	Adenocarcinoma	Mutation negative	Negative	–	26 days placebo	Progressive disease (day 25)	None	Progressive disease	KIF5B	75–100%
ZEST**	70	M	White	Ex-smoker	Adenocarcinoma	Mutation negative; amplification positive	Negative	–	315 days erlotinib	Progressive disease (day 166)	None	Progressive disease	Not known	25–50%

F, female; M, male. *Non-smoker = never smoked >20 g tobacco in lifetime; ex-smoker = stopped smoking ≥1 year ago; occasional smoker = <1 tobacco product per day; habitual smoker = ≥1 tobacco product per day. **RET rearrangements with unknown, non-KIF5B fusion partners.